All Hospira articles
-
Business
US court denies Amgen appeal over Pfizer biosimilar
Amgen has lost its bid to compel Pfizer to divulge information about its version of anaemia drug Epogen
-
Business
Pfizer pulls back on UK and Ireland facilities
€400 million manufacturing plant expansion cancelled and two facilities to close
-
Business
Pfizer to sell Hospira Infusion Systems to ICU Medical
$1bn deal brings together medical device units, as Pfizer focuses on Hospira’s biosimilars and generics
-
Business
Hospira buyout is a shot in the arm for Pfizer’s biosimilars
$17bn deal, intended to bolster sterile injectable and biologics capabilities, will be financed with existing cash and new debt
-
Business
First biosimilar antibody drugs approved in Europe
European commission gives final approval to generic infliximab copies
-
Business
Biosimilar drugs step up complexity
First generic monoclonal antibodies recommended for approval in Europe